AAP
RAPP

Arax Advisory Partners’s Rapport Therapeutics RAPP Stock Holding History

Arax Advisory Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500
Closed -$15.2K – 4418
2025
Q4 		$15.2K Sell
500
-64
-11% -$1.77K ﹤0.01% 2264
2025
Q3 		$16.8K Buy
+564
New +$10.1K ﹤0.01% 2355

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Arax Advisory Partners's RAPP Position: Q1 2026 in Review

Arax Advisory Partners sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 500 shares — an estimated $15.2K sold.

Arax Advisory Partners first reported a position in RAPP in Q3 2025 and held it in 2 quarters. The position peaked at $16.8K in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Arax Advisory Partners reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 500 Rapport Therapeutics shares in Q1 2026, an estimated $15.2K.
  • Arax Advisory Partners first reported a position in Rapport Therapeutics in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Rapport Therapeutics position peaked at $16.8K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.